Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$98.70 USD

98.70
1,938,776

+1.59 (1.64%)

Updated May 16, 2024 03:59 PM ET

After-Market: $98.72 +0.02 (0.02%) 6:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.

AngioDynamics (ANGO) Settles Patent Litigations With BD

by Zacks Equity Research

AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes

by Zacks Equity Research

Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.

Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution

by Zacks Equity Research

Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).

Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio

by Zacks Equity Research

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp

by Zacks Equity Research

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

Here's Why Investors Should Buy ResMed (RMD) Stock Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

by Zacks Equity Research

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch

by Zacks Equity Research

The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval

by Zacks Equity Research

Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume

by Zacks Equity Research

GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Shockwave Medical (SWAV) Up on Potential Acquisition Rumors

by Zacks Equity Research

Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.

Zacks.com featured highlights include General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive

by Zacks Equity Research

General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive are part of the Zacks Screen of the Week article.

Boston Scientific (BSX) and Scivita Medical Expand Partnership

by Zacks Equity Research

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).